Recycled Blood Superior to Banked Blood for Surgery
|
By LabMedica International staff writers Posted on 25 May 2014 |
Patients whose own red blood cells (RBCs) are recycled during cardiopulmonary bypass (CPB) surgery fare better than those who get transfusions from a blood bank, according to a new study.
Researchers at Johns Hopkins Medicine (Baltimore, MD, USA) conducted a prospective cohort study involving 32 patients undergoing cardiac surgery with CPB. The patients were divided into three groups by transfusion status: autologous salvaged RBCs alone (12 patients), autologous salvaged RBCs + minimal (less than five units) stored allogeneic RBCs (10 patients), and autologous salvaged RBCs + moderate (more than five units) stored allogeneic RBCs (10 patients). Ektacytometry was used to measure RBC deformability and aggregation before, during, and for three days after surgery.
The results showed that in patients who received only their own RBCs, elongation index did not change significantly from the preoperative baseline. The more blood a patient got from the blood bank, the more their RBCs deformed; deformability was dose-dependent, recovering toward baseline over time. Three days after surgery, however, the RBCs in the group that got the largest number of transfused units still had not recovered their full function. Changes in aggregation were unrelated to transfusion. The study was published in the June 2014 issue of Anesthesia & Analgesia.
“We now have more evidence that fresh blood cells are of a higher quality than what comes from a blood bank,” said lead author Steven Frank, MD, an associate professor of anesthesiology and critical care medicine. “If banked blood, which is stored for up to six weeks, is now shown to be of a lower quality, it makes more sense to use recycled blood that has only been outside the body for one or two hours. It's always been the case that patients feel better about getting their own blood, and recycling is also more cost effective.”
Blood recycling is achieved via a cell saver machine, which collects blood lost during surgery, rinses away unneeded fat and tissue, and then centrifuges and separates the RBCs, which are returned to the patient. Patients who lose blood may also need platelets and plasma, which they receive regardless of whether they receive their own blood or blood from a bank. Recycling first became popular during the early years of the HIV/AIDS crisis, so that patients could avoid the risk of getting the virus in transfused blood. The practice also reduces the risk of contracting hepatitis B or C infections, or of bad transfusion-related reactions.
Related Links:
Johns Hopkins Medicine
Researchers at Johns Hopkins Medicine (Baltimore, MD, USA) conducted a prospective cohort study involving 32 patients undergoing cardiac surgery with CPB. The patients were divided into three groups by transfusion status: autologous salvaged RBCs alone (12 patients), autologous salvaged RBCs + minimal (less than five units) stored allogeneic RBCs (10 patients), and autologous salvaged RBCs + moderate (more than five units) stored allogeneic RBCs (10 patients). Ektacytometry was used to measure RBC deformability and aggregation before, during, and for three days after surgery.
The results showed that in patients who received only their own RBCs, elongation index did not change significantly from the preoperative baseline. The more blood a patient got from the blood bank, the more their RBCs deformed; deformability was dose-dependent, recovering toward baseline over time. Three days after surgery, however, the RBCs in the group that got the largest number of transfused units still had not recovered their full function. Changes in aggregation were unrelated to transfusion. The study was published in the June 2014 issue of Anesthesia & Analgesia.
“We now have more evidence that fresh blood cells are of a higher quality than what comes from a blood bank,” said lead author Steven Frank, MD, an associate professor of anesthesiology and critical care medicine. “If banked blood, which is stored for up to six weeks, is now shown to be of a lower quality, it makes more sense to use recycled blood that has only been outside the body for one or two hours. It's always been the case that patients feel better about getting their own blood, and recycling is also more cost effective.”
Blood recycling is achieved via a cell saver machine, which collects blood lost during surgery, rinses away unneeded fat and tissue, and then centrifuges and separates the RBCs, which are returned to the patient. Patients who lose blood may also need platelets and plasma, which they receive regardless of whether they receive their own blood or blood from a bank. Recycling first became popular during the early years of the HIV/AIDS crisis, so that patients could avoid the risk of getting the virus in transfused blood. The practice also reduces the risk of contracting hepatitis B or C infections, or of bad transfusion-related reactions.
Related Links:
Johns Hopkins Medicine
Latest Hematology News
- Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
- New Marker Helps Detect Aggressive Multiple Myeloma Earlier
- New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
- AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
- Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
Channels
Clinical Chemistry
view channel
Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
Accurate diabetes detection is essential because early identification guides timely management, yet test performance can vary in people with hemoglobin variants such as sickle cell trait.... Read more
Blood Protein Panel Predicts Timing of ALS Symptom Onset
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which clinical signs often emerge only after substantial motor neuron injury has already occurred, complicating timely intervention.... Read moreMolecular Diagnostics
view channel
AI Tool Improves Long-Read Detection of Cancer Mutations
Accurate identification of somatic mutations remains difficult, particularly in structurally complex genomic regions. Short-read sequencing pipelines can miss clinically relevant variants, limiting research... Read more
FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
Vaginitis is a common reason for clinical visits, with bacterial vaginosis and Candida vaginitis among the leading causes. Overlapping symptoms and reliance on microscopy, pH testing, and clinical observation... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read more
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read morePathology
view channel
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelLumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more








